Memoria 2020

20 20

Annual Annual 20 report Annual report 2020 20 report

"Nowhere is it written that Alzheimer's is invincible"

Pasqual Maragall October, 2007

Wellington, 30 08005 Barcelona 933 160 990 [email protected] [email protected] www.fpmaragall.org www.barcelonabeta.org

20 20A key year for science Edition Pasqual Maragall Foundation Barcelonaßeta Brain Research Center Foundation Wellington, 30 08005 Barcelona 933 160 990 [email protected] [email protected] www.fpmaragall.org www.barcelonabeta.org

Art direction marcmontala.com

Publication date June 2021

Total or partial reproduction of this publication, treatment in any form or by any means, electronic, mechanical, photocopying, recording, or other methods, or its loan, rent or any other form of cession of use of the copy is not allowed without prior written permission of the copyright holder. 20

Annual 20 report

Greeting 06

Determination 08 Alzheimer’s disease today 09 2020: moving forward despite the pandemic 10 The year in numbers 12

Credibility 14 The year in ﬁgures 15 Alfa Study 16 Alzheimer’s Prevention Program 17 Research projects 20 International consortia 26 Clinical trials 29 Publications 30 Dissemination of results 32 Scholarships and competitive grants 34 Conferences 36

Transformation 38 Therapeutic groups 39 Awareness and outreach activities 41

Connection 52 Partner and donor team 53 Unforgettable actions and entities 55 Solidarity wills 59

Trust 60 About us 61 Origin and destination of resources 62 Collaborators 64 Academic collaborators 65 Board 66 Greeting Annual report 2020 06

Greeting

The entity's annual report is the occasion to render accounts and In terms of research, we have continued to analyse the data genera- also to take stock of the work done. Being at the header of the first ted by the Alfa Study developed thanks to the encouragement of pages is an important responsibility for any director. This year is Fundación “la Caixa”. Also, after a period of stoppage due to the pande- also special for our sector, for all those who dedicate ourselves to mic and confinement, we have restarted the visits to the participants. science, for people who suffer from Alzheimer's disease and their families, and in general for everyone who is experiencing this In addition, we have detected findings as important as discovering situation of uncertainty as a result of the Covid-19 pandemic. that one of the biomarkers of a protein linked to Alzheimer's disease can be used to detect the disease in the early stages with a blood test, A little over a year ago, I accepted the task of directing this entity and other scientific breakthroughs related to risk factors of the jointly with my predecessor, Dr. Jordi Camí. I faced it stimulated by the disease derived from insomnia, pollution or parental age. As a challenge, objective and determination to end Alzheimer's disease and result of all our growing scientific activity, this year we have participated knowing that I was facing a very well done job, of a solid entity with in over 60 scientific articles. very well-established foundations to build a good future. Regarding our social aspect and our commitment to support people The new stage as a director began with the unexpected death of our suffering from Alzheimer's disease and their families, we have maintai- president, Diana Garrigosa, who we continue to miss every day for her ned online and face-to-face therapeutic groups. Likewise, since the personal worth and drive. Diana's transfer brought her daughter Cristina beginning of the pandemic, through our blog called “Hablemos del Maragall to the presidency of the Foundation, whom I thank for her trust. Alzheimer” we have accompanied families with current information adapted to the situation. And right after the organizational changes and with no time to recover from Diana's death, the worst pandemic that humanity has experienced We have also carried out different activities to emphasize the need to in the last 100 years broke out. invest in research before the authorities or on September 21, World Alzheimer's Day, through the initiative #UnDíaParaOlvidar. We have also Covid-19 has impacted our lives and has forced us to find new ways of worked to change the social perception of the disease through the publi- relating to one another, of understanding the world and of doing our jobs; cation of the “Encuesta de Actitudes y Percepciones sobre el Alzheimer” to be imaginative in solving problems we never thought we would have, (survey of attitudes and perceptions on Alzheimer's disease), and other but, above all, the pandemic has confirmed the value of research. Thanks initiatives. to science, we are facing the most rapidly solved health problem in the history of mankind. This is only a small summary of a very intense year. I invite you to read and find all the information on these pages. And also with science we will defeat Alzheimer's disease. We will do this together! Thanks to Patrons, Sponsors, the more than 45,000 Partners, Thanks again to our Patrons, Board of Trustees, Partners, Collaborators, Donors and Collaborators, and also the team of the Pasqual Maragall Foun- Study Participants and Volunteers for joining us in fulfilling our common dation, we are closer to achieving a world free of neurodegenerative diseases. commitment to defeat Alzheimer's disease. Have no doubt that we will make it possible. In these pages you will see the intense activity of the Foundation during 2020; the pandemic has not stopped us. On the contrary, we have maintained projects and we have started new ones. Arcadi Navarro Director

Barcelona, june 2020 Annual report 2020 Greeting 07

The entity's annual report is the occasion to render accounts and In terms of research, we have continued to analyse the data genera- also to take stock of the work done. Being at the header of the first ted by the Alfa Study developed thanks to the encouragement of pages is an important responsibility for any director. This year is Fundación “la Caixa”. Also, after a period of stoppage due to the pande- also special for our sector, for all those who dedicate ourselves to mic and confinement, we have restarted the visits to the participants. science, for people who suffer from Alzheimer's disease and their families, and in general for everyone who is experiencing this “The pandemic In addition, we have detected findings as important as discovering situation of uncertainty as a result of the Covid-19 pandemic. has confirmed the that one of the biomarkers of a protein linked to Alzheimer's disease can be used to detect the disease in the early stages with a blood test, A little over a year ago, I accepted the task of directing this entity value of investigation. and other scientific breakthroughs related to risk factors of the jointly with my predecessor, Dr. Jordi Camí. I faced it stimulated by the Thanks to science, disease derived from insomnia, pollution or parental age. As a challenge, objective and determination to end Alzheimer's disease and we are facing the most result of all our growing scientific activity, this year we have participated knowing that I was facing a very well done job, of a solid entity with in over 60 scientific articles. very well-established foundations to build a good future. rapidly solved health problem in the history Regarding our social aspect and our commitment to support people The new stage as a director began with the unexpected death of our of mankind. And also suffering from Alzheimer's disease and their families, we have maintai- president, Diana Garrigosa, who we continue to miss every day for her with science we will ned online and face-to-face therapeutic groups. Likewise, since the personal worth and drive. Diana's transfer brought her daughter Cristina beginning of the pandemic, through our blog called “Hablemos del Maragall to the presidency of the Foundation, whom I thank for her trust. defeat Alzheimer's Alzheimer” we have accompanied families with current information disease” adapted to the situation. And right after the organizational changes and with no time to recover from Diana's death, the worst pandemic that humanity has experienced We have also carried out different activities to emphasize the need to in the last 100 years broke out. invest in research before the authorities or on September 21, World Alzheimer's Day, through the initiative #UnDíaParaOlvidar. We have also Covid-19 has impacted our lives and has forced us to find new ways of worked to change the social perception of the disease through the publi- relating to one another, of understanding the world and of doing our jobs; cation of the “Encuesta de Actitudes y Percepciones sobre el Alzheimer” to be imaginative in solving problems we never thought we would have, (survey of attitudes and perceptions on Alzheimer's disease), and other but, above all, the pandemic has confirmed the value of research. Thanks initiatives. to science, we are facing the most rapidly solved health problem in the history of mankind. This is only a small summary of a very intense year. I invite you to read and find all the information on these pages. And also with science we will defeat Alzheimer's disease. We will do this together! Thanks to Patrons, Sponsors, the more than 45,000 Partners, Thanks again to our Patrons, Board of Trustees, Partners, Collaborators, Donors and Collaborators, and also the team of the Pasqual Maragall Foun- Study Participants and Volunteers for joining us in fulfilling our common dation, we are closer to achieving a world free of neurodegenerative diseases. commitment to defeat Alzheimer's disease. Have no doubt that we will make it possible. In these pages you will see the intense activity of the Foundation during 2020; the pandemic has not stopped us. On the contrary, we have maintained projects and we have started new ones. Arcadi Navarro Director

Barcelona, june 2021 deter mina tion.

"Nowhere is it written that Alzheimer's is invincible"

Pasqual Maragall said it, and we will not tire of working to achieve a future without Alzheimer's or neurodegenerative diseases. The pandemic signiﬁcantly aﬀected the way we work, but we quickly and determinedly adapted to move forward with our mission.

01. Annual report 2020 Alzheimer's today 09

1.01

Every year 10 million cases of dementia are registered around the world, most Alzheimer's of them caused by Alzheimer's, which implies a new diagnosis every 3 seconds1. At the Pasqual Maragall Foundation and the Barcelonaβeta Brain Research today Center we are convinced that the Scientiﬁc research, together with social awareness and dissemination, is the only way to stop Alzheimer's.

50 Millions 800.000 cases cases

Every year 10 million Every 3 seconds a new case of dementia 1 in 10 people over the age cases of dementia are is diagnosed in the world. of 65 suﬀers from Alzheimer's. registered around the world, most of them caused by Alzheimer's. 64% 70% 47% 44% Alzheimer’s Cancer Stroke Covid-19

Alzheimer's (64%) and cancer (70%) are the most worrying health conditions for Spaniards, ahead of stroke (47%), and Covid-19 (44%)

2 out of 3 Spaniards have or have had in their environment a person aﬀected by Alzheimer's

8 out of 10 families take care of the aﬀected person and up to 87% of the total cost on average

Caregivers dedicated an average of 4 more hours a day +4h to their Alzheimer's relatives during conﬁnement

1. Data of OMS and World Alzheimer Report. 2. Brain Foundation Data: Social Impact of Alzheimer's Disease and Other Dementias. 3. Data from the Pasqual Maragall Foundation: “Survey on the eﬀect of Covid-19 on people with Alzheimer's and their caregivers”. 4. Data from the Pasqual Maragall Foundation: Survey “Attitudes and perceptions of the Spanish population about Alzheimer's disease”, prepared by the Pasqual Maragall Foundation. 2020: moving forward despite the pandemic Annual report 2020 10

1.02 2020: moving forward despite the pandemic

January July August New evidence May We listen to We discovered We found evidence that Scientific findings caregivers a new risk factor could link insomnia with People most exposed to air Concerned about the In our research center, we Alzheimer's. Our study pollution have greater brain possible worsening of determined a new risk factor reveals evidence that atrophy and less cortical dementia symptoms in for developing the disease: people with sleep disorders thickness in specific areas those who suffer from it proximity to the parental have poorer cognitive of the brain linked to and about the well-being age of onset of Alzheimer's performance and lower Alzheimer's disease. of their caregivers during symptoms in women. volume in some brain We prove it in a new study. confinement, we conducted regions linked to a survey of caregivers in our Alzheimer's disease. therapeutic groups.

July March July We demand the protection We adapt The peseta returns of people with dementia to the new reality We give the peseta a We urge the Government With the emergence of Last Mission. We collect to prioritize the care of people Covid-19, we promoted in forgotten pesetas in the in situations of fragility or our blog a series of articles drawers of thousands of dependency, as well as to provide with tips to manage the homes in the country to resources for research on health crisis situation with transform them into Alzheimer's and other dementias, people with Alzheimer's research. in to the non-permanent and we continue to Commission for Social and accompany aﬀected Economic Reconstruction of the families through virtual Congress of Deputies. therapeutic groups. Annual report 2020 2020: moving forward despite the pandemic 11

December For the promotion of science September November We listen Advancement We adhere to the Pact for to society in early detection Science and Innovation November promoted by the Alzheimer's equals A new ﬁnding brings us Commitment Government to increase cancer as the disease closer to the early detection and cooperation resources, reinforce the role of greatest concern: of Alzheimer's through a We joined the board of funding agencies and we published data on simple blood test. New of directors of the attract and retain talent the survey “Attitudes markers for the tau protein are Catalan Coordinator from the world of science, and perceptions of the able to detect the preclinical of Foundations (CCF). and to the State Board for Spanish population on phase of Alzheimer's disease in the Rights of the Elderly. Alzheimer's disease”. blood and cerebrospinal ﬂuid.

December October November The power of music September The festival We disseminate European The “Life Soundtrack” of the brain knowledge recognition project unites, for yet We celebrate the 3rd We promote the another year, young people One of our researchers, edition of the Brain “Remember” series and people with dementia Dr. Marc Suárez-Calvet, Film Fest, the of talks to inform about through music. obtained the prestigious international festival of Alzheimer's research, European grant “ERC cinema about the brain, oﬀer advice for people Starting Grant” to with the participation of living with the disease identify blood factors Viggo Mortensen. and answer questions that rejuvenate the from our partners and brain. followers.

Research Social The year in ﬁgures Annual report 2020 12

1.03

The year Budget in ﬁgures Budget € 11,565,308

Pasqual Maragall Foundation € 7,241,947

Aggregated data from BBRC Research Center the Pasqual Maragall € Foundation and the 4,323,361 Barcelonaβeta Brain Research Center. 63 % FPM 37 % BBRC The annual accounts of the two entities are audited by an independent Human team auditing

136 People 32 % 68 % 44 Men 92 Women

Pasqual Maragall BBRC Foundation Research Center

82 54 People People 31 % 69 % 33 % 67 % 26 Men 56 Women 18 Men 36 Women Annual report 2020 The year in ﬁgures 13

20 20 Divulgation 1,750 + 73,000 + 1,347,000 Appearances Followers on Visits to the Blog in the media social networks "Let's talk about Alzheimer's"

19 207 Therapeutic groups in Barcelona, 158 Individual telematic Girona, Lleida, Tenerife, Seville, Participating emotional support caregivers Alcalá de Henares, Madrid, Vigo interventions and Valencia

Investigation

+1,300 + 4,600 + 600 Visits to Samples Magnetic participants processed resonances

Social support

41,290 + 2,700 82 Members at Donations Solidarity the end of the year initiatives cre dibi lity.

Scientiﬁc rigor and expert knowledge in everything we do.

At the Barcelonaβeta Brain Research Center (BBRC) we are dedicated to Alzheimer's prevention research. Thanks to the experience, rigor and high competence of our scientiﬁc team, we are contributing new knowledge to one day be able to prevent, or at least delay, the onset of the disease.

02. Annual report 2020 Figures 15

2.01

Figures

+ 4,600 + 1,300 + 600 Samples Visits to Magnetic processed participants* resonances

The COVID-19 pandemic forced us to suspend the visits of our 15 scientiﬁc projects for 3 and Study a half months, coinciding protocols with the period of strict conﬁnement.

In July, they gradually resumed incorporating security protocols and prevention of COVID-19, extending the time of the sessions. + 1.000 Sessions As a consequence, the number of visits to participants in 2020 is signiﬁcantly lower than in previous years.

27.8 % 25.8 % 46.4 % Nursing Cognition Clinical sessions sessions sessions

*In the same visit the participants can carry out diﬀerent sessions. Alfa Study Annual report 2020 16

2.02

The Alfa Study is a research platform Alfa dedicated to the early detection and prevention of Alzheimer's disease, Study which stands out internationally for its number of participants and the large volume of information available to them. Launched in 2013 thanks to the encouragement of the “la Caixa” In the ﬁrst visit of the Alpha Study, the Foundation, it is made up of more participants provided their medical than 2,700 participants without history and performed a series of cognitive alterations, between 45 cognition and nursing tests, comple- and 75 years old, most of whom are ted lifestyle questionnaires, and had sons and daughters of people with blood drawn to obtain information on Alzheimer's. Its objective is to collect their APOE gene genotype. information that allows the identiﬁca- tion of biomarkers and risk factors The participants were later invited to to understand the natural history of participate in research projects, such Alzheimer's disease and to design as Alpha +, which also included other prevention strategies. additional tests such as positron emission tomography (PET), lumbar 2.700 puncture, magnetic resonance imaging or olfaction test. Participants

The exhaustive characterization of the participants through periodic testing is what makes the Alpha Study a valuable research infrastructure for conducting prevention clinical trials. BBRC researchers publish numerous relevant advances in prestigious scientiﬁc journals thanks to the exploitation of the data generated through the study.

The Alfa Study is supported by: Annual report 2020 Alzheimer's prevention program 17

2.03

The BBRC Alzheimer's Prevention The researchers continued to publish Alzheimer's Program is divided into two research results, participate in the main groups: the Neuroimaging group, led scientiﬁc conferences virtually, prevention by Dr. Juan Domingo Gispert, and the and obtain highly competitive scholars- Clinical Research, Biomarkers and hips and projects. In addition, they program Risk Factors group, led by Dr. José were able to continue analyzing data Luis Molinuevo until October 2020. remotely, thanks in part to the The Program closed the year with 19 digitization process that the center researchers on staﬀ. has led in recent years.

The Program's research focuses on Discover the projects the prevention of Alzheimer's and healthy aging from a clinical, cogniti- in which the BBRC resear- ve, genetic, fluid marker and neuroi- 1 chers were immersed maging perspective. The focus of during confinement, study is on the preclinical phase of the Neuroimaging with the video series disease, which includes a period of up Research Group #laCienciaNoPara to 20 years prior to the appearance of the first clinical symptoms, in which certain changes in the brain associa- The Neuroimaging Research Group ted with Alzheimer's already occur. specializes in the analysis of Magnetic Resonance Imaging and Positron Despite the emergence of COVID-19 Emission Tomography (PET) images and the temporary suspension of to reveal brain characteristics related visits to participants in the Alfa to healthy aging and risk factors for Study and other projects, the Alzheimer's disease. The team is led scientific production of the BBRC by Dr. Juan Domingo Gispert, and was not affected. made up of experts in the acquisition, processing and analysis of neuroimaging data.

In addition to the studies led by the BBRC, during 2020 it actively collaborated with the European consortium EPAD and AMYPAD, the Cardiovascu- lar Research Center (CNIC), the Polytechnic University of Barcelona (UPC), the Barcelona Supercomputing Center (BSC-CNS), and the Center for Genomic Regulation (CRG), among others. Alzheimer's prevention program Annual report 2020 18

2.03

Lines of investigation

The aim of the group Correlations between brain New techniques for detecting the is to reveal brain structure and risk factors for preclinical phase of Alzheimer's characteristics that Alzheimer's in the preclinical disease. phase of the disease. can be suggestive of Generation of a repository of novel prevention Improving the use of amyloid PET images of the preclinical phase strategies. images in clinical and research of Alzheimer's disease. settings.

Genetic determinants of brain phenotypes.

2 Clinical Research Group, Biomarkers and Risk Factors

The Clinical Research Group, The members of the group collabora- Biomarkers and Risk Factors te on multiple projects with other analyzes the biological processes that research teams from the Alzheimer's precede the onset of the symptomatic Association network, the EPAD phases of Alzheimer's, in order to be consortium, the University of able to design programs aimed at Göteborg, the Barcelona Institute for people at risk of suﬀering from the Global Health (ISGlobal), the Hospital disease in order to stop or at least del Mar Medical Research Institute delay the incidence of cognitive (IMIM) and the August Pi i Sunyer decline and, lastly, dementia. Biomedical Research Institute (IDIBAPS), among others. The research group is made up of a team of experts in the ﬁeld of Alzheimer's disease pathophysiology, biomarkers, genetics, neuropsycholo- gical evaluation, and lifestyle habits and risk factors for the disease. Annual report 2020 Alzheimer's prevention program 19

2.03

Lines of investigation

The aim of the Association between subjective Epidemiological studies on group is establishing cognitive impairment and brain the role of pollution, anxiety, prevention programs changes and objective cognitive depression and other factors performance. in Alzheimer's. for people who have no symptoms but are Association between sleep Eﬀects of conﬁnement due to the at risk of developing disorders, cognitive impairment COVID-19 pandemic on mental the disease. and Alzheimer's disease. and brain health.

Analysis and development of ﬂuid Eﬀect of dietary intake of omega-3 biomarkers of the preclinical phase fatty acids in the preclinical phase of Alzheimer's. of Alzheimer's.

Study of the personalized risk of Multimodal interventions developing dementia to oﬀer for the prevention of cognitive personalized prevention plans. impairment.

Role of vascular risk factors Study of reserve, resilience and in the pathophysiology lifestyle to understand brain of Alzheimer's. mechanisms and risk factors that make some people resilient to disease. Research projects Annual report 2020 20

2.04

Research 1 2 projects HeBe Study on the Impact of home confinement during the Covid-19 pandemic on the brain HeBe is a new research project that will start in 2021, led by Dr. Marc and mental health Suárez Calvet, under the umbrella of the prestigious European ERC Starting The HeBe project Grant. Named after the Greek goddess of eternal youth, it has an expected In 2020, a new study was launched to receives funding from duration of 5 years. analyze the effects of confinement the European Research on mental and brain health, as well Council within the Although we know that aging is the as other factors that mitigate its framework of the main risk factor for the development impact. The project was joined by European Union's of Alzhei-mer's and other neurodege- more than 900 BBRC participants Horizon 2020 research nerative diseases, the mechanisms without cognitive alterations, between behind this association are still 45 and 75 years old and descendants, and innovation program. unknown. The main objective of HeBe most of them, of people with Alzhei- is to investigate these mechanisms mer's. by identifying brain rejuvenation factors in the blood to use them as Participants completed a series of therapeutic targets for Alzheimer's online questionnaires during confine- disease. ment and will do so again about 18-24 months later so researchers can assess To identify these blood factors, outcomes related to anxiety, depres- the researchers will determine the sion, and post-traumatic stress biological age of the Alpha Study disorder. participants, and will analyze whether there are blood factors that differ This project aims to detect if there are among participants with extreme brain changes related to Alzheimer's biological ages; that is, participants disease and to study the impact of with much lower biological ages confinement in people in the Alpha versus those with much higher study, with special emphasis on those biological ages than their chronologi- who are caring for a family member cal ages. HeBe's main hypothesis is with dementia or other diseases that that there are factors in the blood imply dependency or special needs. that explain the differences between biological and chronological age. Annual report 2020 Research projects 21

2.04

3 4

Alfa Sleep Alfa+

Alfa Sleep is a new study that will Alfa+ is a prospective, observational deepen the relationship between cohort study for the early identifica- insomnia and Alzheimer's. The project tion of biomarkers associated with contemplates visiting 200 partici- the preclinical phase of Alzheimer's pants starting in 2021, and has an disease, prior to the symptomatic expected duration of 2 years. phases of the disease. In 2020, 584 visits to this study were carried out at Alfa Sleep is funded In the study, polysomnographies will the BBRC facilities. be performed, actigraphs will be used by the Alzheimer's and the levels of the neuropeptide Some 420 people without cognitive Association and the orexin, key in sleep regulation, will be impairment participate in the project Carlos III Health analyzed. These tests, together with and every three years different tests Institute. others carried out in the Alfa + study, are carried out, such as cognitive tests, provide very precise and reliable extraction of cerebrospinal fluid by objective data to study the association lumbar puncture, nursing tests and between different sleep parameters, two MRIs. Participants are also invited biochemical changes, and changes in to undergo PET tests at the facilities of brain structure and functionality. the Hospital Clínic de Barcelona. The visits will start in 2021.

420 Participants Research projects Annual report 2020 22

2.04

Alfa Genetics

Its objective is Alfa Genetics is a cross-sectional In this way, the aim is to identify brain to improve the study designed to broaden the patterns associated with genetic knowledge of the cognitive, genetic and brain variants related to the risk of characterization of the participants developing Alzheimer's. molecular bases in the Alfa Study. Its objective is of Alzheimer's and to improve the knowledge of the The visits to this study ended in 2019, identify new markers molecular bases of Alzheimer's and and throughout 2020 the data and risk factors. identify new markers and risk factors collected continued to be analyzed to to be able to detect the disease early. publicize the main results of the study.

Tests performed on the nearly 1,700 study participants include an MRI, an odor identiﬁcation test, a blood draw, and an update of medical history and cognitive tests. Annual report 2020 Research projects 23

2.04

6 have measured them in 400 blood samples from participants in the Bio Alfa Alfa+ cohort.

In 2020 the study completed its main objective, that of measuring blood The Bio Alfa project aims to investiga- factors related to aging and brain te whether certain blood factors that rejuvenation, and the data is in the have been associated with aging or process of analysis to lead to the brain rejuvenation in mice can publication of the main results Bio Alfa has been led by become potential therapeutic targets throughout 2021. Dr. Marc Suárez-Calvet, to combat Alzheimer's disease and other dementias in humans. The line Research on these blood and funded by the Marie Since it was launched in 2018, factors started in the Bio Alfa project Skłodowska-Curie grant researchers have studied these will continue with the HeBe project. number 752310, within factors in blood samples from the framework of the participants of extreme ages, and European Union's Horizon 2020 research and innovation program.

The Blood and Tissue Bank, the Walnuts Study of the Barcelona Global Health Institute and the ”la Caixa” Foundation, which supports the Alfa+ Study, have also collaborated in the project. Research projects Annual report 2020 24

2.04

7 8

Alfa Cognition Clinical Research Unit in Dementia Prevention

Alfa Cognition is an observational and prospective study that analyzes the relationship between the The study analyzes the subjective perception of cognitive The Clinical Research Unit in relationship between the decline and the presence, evolution Dementia Prevention is a project subjective perception of or risk of clinically objective cognitive that studies the risk and biological cognitive decline and the impairment. bases of developing dementia ﬁve presence, evolution or years from now. The study oﬀers risk of clinically objective It also analyzes the relationship participants a personalized action cognitive impairment. between these parameters and the plan to try to reduce their risk. brain changes associated with Alzheimer's disease. The study incorporates a total of about 300 participants between the 200 people participated in the study, ages of 60 and 80 who are experien- performing neurological, neuroima- cing a decline in their cognitive ging, cognitive and lifestyle tests, and abilities. a blood draw. In 2020 there were 75 visits to this study. In 2020, a total of 608 visits were made to study participants and, of these, 13 completed the program, which consists of a follow-up of approximately one year.

300 Participants Annual report 2020 Research projects 25

2.04

PENSA Study

The PENSA Study is part The PENSA study is a clinical trial that The participants are people between of the international aims to study whether it is possible to 60 and 80 years old who are experien- consortium World Wide slow down cognitive deterioration in cing a decline in memory or other FINGERS, an initiative stages prior to the onset of dementia cognitive abilities such as attention, dedicated to promoting through the promotion of healthy planning capacity or orientation, lifestyle habits and the intake of among others. projects for the primary epigallocatechin gallate (EGCG), prevention of cognitive a component natural green tea. Through a personalized action plan im-pairment and based on lifestyle habits and health dementia. The project is led by the BBRC and the indicators, during the course of the Hospital del Mar Medical Research study, participants will be helped to The project is funded Institute (IMIM), and was launched in carry out appropriate changes to try with a million dollars December 2019 with an expected to reduce the risk of cognitive by the Alzheimer's duration of 17 months. In 2020, a total impairment. Association of the of 358 participants were recruited, United States. of which about 50 began visits at the BBRC. International consortia Annual report 2020 26

2.05

Interna- 1 tional Blood tests to detect consortia amyloid pathology

Researchers from the University of The new system will be designed so Göteborg, the University of Lund, that it can be implemented in primary Roche Diagnostics International and care centers, and to identify indivi- the BBRC launched the project 'Fully duals with brain amyloid pathology. automated plasma assays as screening tests for Alzheimer-related amyloid Their method will be tested in cohort The program is funded beta (Aβ) pathology' 'in March. Its study participants from BBRC, the by the Alzheimer's Drug objective is to develop a detection Swedish BIOFINDER cohort, and 15 Discovery Foundation. and triage algorithm based on blood healthcare centers in Sweden. biomarker analysis to detect amyloid pathology. Annual report 2020 International consortia 27

2.05

EPAD was funded by Grant Number 115736 from the Innovative Medicines Initiative, which is a joint initiative of the European Commission Horizon 2 from various centers across Europe, 2020 research and including 205 non-cognitively innovation program EPAD impaired individuals from the BBRC and the European Alfa Study. Federation of Pharma- ceutical Industries and The Barcelonaβeta Brain Research 2020 was the closing year of one Center has served as Iberian Lead and Associations (EFPIA). of the most ambitious and funded has managed to be the number one projects in the ﬁeld of Alzheimer's country in recruitment capacity. prevention research in the world: Thanks to the collaboration of BBRC, the European Prevention of Alzhei- Hospital Clínic de Barcelona, Funda- mer's Dementia Consortium (EPAD). ción CITA and Fundación ACE, almost 25% of the participants in the EPAD After 5 years, the consortium has study have been recruited. managed to make available to the scientiﬁc community a set of carefully The consortium has been made up characterized data to expand the of 38 European institutions, coming knowledge of the earliest stages of from research centers, universities, Alzheimer's disease. European pharmaceutical laborato- ries and patient associations. The EPAD database contains clinical, cognitive, neuroimaging and biomar- More information: www.ep-ad.org ker information on 2,096 participants International consortia Annual report 2020 28

2.05

3 4

AMYPAD TRIBEKA

The Amyloid Imaging to Prevent TRIBEKA is an initiative of the Alzheimer's Disease (AMYPAD) Barcelonaβeta Brain Research Center project is a European collaboration to and the University of Edinburgh, improve the understanding, diagnosis promoted to identify brain alterations and treatment of Alzheimer's through prior to the onset of symptoms of the use of brain amyloid PET. The Alzheimer's disease and other AMYPAD is funded by consortium is made up of 17 European neurodegenerative diseases. institutions, including the BBRC and grant number 115952 other research centers, industry, and The platform has made available to the from program 2 of the associations of people and their families scientiﬁc community a neuroimaging Innovative Medicines with Alzheimer's. database with widely characterized Initiative, which is a joint information on healthy middle-aged initiative of the European AMYPAD closed the recruitment of its people, with the aim of advancing in the Commission Horizon diagnostic study in October, which aims design of treatments against the disease. 2020 research and inno- to determine the value of amyloid PET The information is accessible through as a diagnostic and therapeutic marker. the website of the Global Alzheimer’s vation program and the 844 people from all over Europe Association Interactive Network European Federation of participated in this study, of which 101 (GAAIN). Pharmaceutical Indus- are BBRC participants. tries and Associations (EFPIA). On the other hand, the consortium also TRIBEKA is funded by the Alzheimer's has a prognostic study underway to Association and an international better understand the natural history charitable foundation. of the disease, which had 754 partici- 200 pants at the close of 2020, of which 176 are from the BBRC. Participants

Overall, in 2020, 219 visits for the diagnostic study and 67 for the progno- sis study were carried out in Barcelona.

More information: https://amypad.eu/ Annual report 2020 Clinical trials 29

2.06

Clinical 1 trials AB1601

In 2020 there were also The objective of AB1601, led by the The 200 study participants will follow-up visits to the pharmaceutical company of Grifols undergo tests such as Positron Araclon Biotech, is to evaluate the Novartis and Amge Emission Tomography (PET), brain eﬃcacy, safety, tolerability and MRI and cognitive tests, among others, Generation I and immune response of the drug in mostly Spanish centers, but also in Generation II clinical ABvac40 in people between 55 France, Italy and Sweden. trials, discontinued and 80 years of age with mild amnesic in 2019. cognitive impairment or in very early stages of the disease. 200 Participants Publications Annual report 2020 30

2.07

In 2020, BBRC Most outstanding Cacciaglia R, Molinuevo JL, Falcón C, JL; ALFA Study. Quantitative infor- Publi- researchers published publications: Arenaza-Urquijo EM, Sánchez-Benavi- mant and self-reports of subjective 66 articles, mainly in des G, Brugulat-Serrat A, Blennow K, cognitive decline predict amyloid Grau-Rivera O, Operto G, Falcón C, Zetterberg H, Gispert JD; ALFA study. beta PET outcomes in cognitively cations prestigious leading Sánchez-Benavides G, Cacciaglia R, APOE-ε4 Shapes the Cerebral unimpaired individuals indepen- scientific journals in Brugulat-Serrat A, Gramunt N, Organization in Cognitively Intact dently of age and APOEε4. Alzhei- the field of Alzheimer's Salvadó G, Suárez-Calvet M, Mingui- Individuals as Reflected by Structu- mers Dement (Amst). 2020 Nov and neurodegenerative llon C, Iranzo Á, Gispert JD, Molinuevo ral Gray Matter Networks. Cereb 11;12(1):e12127. diseases. JL; ALFA Study. Association between Cortex. 2020 Jun 1;30(7):4110-4120. insomnia and cognitive performan- Suárez-Calvet M, Karikari TK, Ashton ce, gray matter volume, and white Milà-Alomà M, Salvadó G, Gispert JD, NJ, Lantero Rodríguez J, Milà-Alomà M, matter microstructure in cogniti- Vilor-Tejedor N, Grau-Rivera O, Gispert JD, Salvadó G, Minguillon C, vely unimpaired adults. Alzheimers Sala-Vila A, Sánchez-Benavides G, Fauria K, Shekari M, Grau-Rivera O, Res Ther. 2020 Jan 7;12(1):4. Arenaza-Urquijo EM, Crous-Bou M, Arenaza-Urquijo EM, Sala-Vila A, González-de-Echávarri JM, Minguillon Sánchez-Benavides G, Gonzá- Wang H, Li T, Barbarino P, Gauthier S, C, Fauria K, Simon M, Kollmorgen G, lez-de-Echávarri JM, Kollmorgen G, Brodaty H, Molinuevo JL, Xie H, Sun Y, Zetterberg H, Blennow K, Suárez-Cal- Stoops E, Vanmechelen E, Zetterberg Yu E, Tang Y, Weidner W, Yu X. vet M, Molinuevo JL; ALFA study. H, Blennow K, Molinuevo JL; ALFA Dementia care during COVID-19. Amyloid beta, tau, synaptic, Study. Novel tau biomarkers Lancet. 2020 Apr neurodegeneration, and glial phosphorylated at T181, T217 or 11;395(10231):1190-1191. biomarkers in the preclinical stage T231 rise in the initial stages of the 66 of the Alzheimer’s continuum. preclinical Alzheimer’s continuum Crous-Bou M, Gascon M, Gispert JD, Alzheimers Dement. 2020 when only subtle changes in Aß Articles Cirach M, Sánchez-Benavides G, Oct;16(10):1358-1371. pathology are detected. EMBO Mol Falcon C, Arenaza-Urquijo EM, Med. 2020 Dec 7;12(12):e12921. Gotsens X, Fauria K, Sunyer J, Arenaza-Urquijo EM, Salvadó G, Nieuwenhuijsen MJ, Luis Molinuevo J; Operto G, Minguillón C, Skouras S, Torner J, Andersson P, ALFA Study. Impact of urban Sánchez-Benavides G, Crous-Bou M, Koush Y, Falcon C, Minguillon C, environmental exposures on Grau-Rivera O, Sala-Vila A, Falcón C, Fauria K, Alpiste F, Blenow K, Zetter- cognitive performance and brain Suárez-Calvet M, Zetterberg H, berg H, Gispert JD, Molinuevo JL; ALFA structure of healthy individuals at Blennow K, Gispert JD, Molinuevo JL; Study. Earliest amyloid and tau 93.9% risk for Alzheimer’s dementia. ALFA Study. Association of years to deposition modulate the influence parent’s sporadic onset and risk of limbic networks during Q1 Environ Int. 2020 May;138:105546. factors with neural integrity and closed-loop hippocampal downre- Schindler SE, Jicha GA, Nelson PT, Alzheimer biomarkers. Neurology. gulation. Brain. 2020 Mar Keene CD, Blennow K, Molinuevo JL, 2020 Oct 13;95(15):e2065-e2074. 1;143(3):976-992. 85.5% Masters CL, Hansson O, Teunissen CE, Galasko D, Shaw LM, Levey AI, Sánchez-Benavides G, Salvadó G, D1 Silverberg N. Maximizing Safety in Arenaza-Urquijo EM, Grau-Rivera O, the Conduct of Alzheimer’s Disease Suárez-Calvet M, Milà-Alomà M, Fluid Biomarker Research in the González-de-Echávarri JM, Minguillon Era of COVID-19. J Alzheimers Dis. C, Crous-Bou M, Niñerola-Baizán A, 2020;76(1):27-31. Perissinotti A, Gispert JD, Molinuevo Annual report 2020 Publications 31

2.07

Most outstanding Cacciaglia R, Molinuevo JL, Falcón C, JL; ALFA Study. Quantitative infor- publications: Publi- Arenaza-Urquijo EM, Sánchez-Benavi- mant and self-reports of subjective des G, Brugulat-Serrat A, Blennow K, cognitive decline predict amyloid Grau-Rivera O, Operto G, Falcón C, cations Zetterberg H, Gispert JD; ALFA study. beta PET outcomes in cognitively Sánchez-Benavides G, Cacciaglia R, APOE-ε4 Shapes the Cerebral unimpaired individuals indepen- Brugulat-Serrat A, Gramunt N, Organization in Cognitively Intact dently of age and APOEε4. Alzhei- Salvadó G, Suárez-Calvet M, Mingui- Individuals as Reﬂected by Structu- mers Dement (Amst). 2020 Nov llon C, Iranzo Á, Gispert JD, Molinuevo ral Gray Matter Networks. Cereb 11;12(1):e12127. JL; ALFA Study. Association between Cortex. 2020 Jun 1;30(7):4110-4120. insomnia and cognitive performan- Suárez-Calvet M, Karikari TK, Ashton ce, gray matter volume, and white Milà-Alomà M, Salvadó G, Gispert JD, NJ, Lantero Rodríguez J, Milà-Alomà M, matter microstructure in cogniti- Vilor-Tejedor N, Grau-Rivera O, Gispert JD, Salvadó G, Minguillon C, vely unimpaired adults. Alzheimers Sala-Vila A, Sánchez-Benavides G, Fauria K, Shekari M, Grau-Rivera O, Res Ther. 2020 Jan 7;12(1):4. Arenaza-Urquijo EM, Crous-Bou M, Arenaza-Urquijo EM, Sala-Vila A, González-de-Echávarri JM, Minguillon Sánchez-Benavides G, Gonzá- Wang H, Li T, Barbarino P, Gauthier S, C, Fauria K, Simon M, Kollmorgen G, lez-de-Echávarri JM, Kollmorgen G, Brodaty H, Molinuevo JL, Xie H, Sun Y, Zetterberg H, Blennow K, Suárez-Cal- Stoops E, Vanmechelen E, Zetterberg Yu E, Tang Y, Weidner W, Yu X. vet M, Molinuevo JL; ALFA study. H, Blennow K, Molinuevo JL; ALFA Dementia care during COVID-19. Amyloid beta, tau, synaptic, Study. Novel tau biomarkers Lancet. 2020 Apr neurodegeneration, and glial phosphorylated at T181, T217 or 11;395(10231):1190-1191. biomarkers in the preclinical stage T231 rise in the initial stages of the of the Alzheimer’s continuum. preclinical Alzheimer’s continuum Crous-Bou M, Gascon M, Gispert JD, Alzheimers Dement. 2020 when only subtle changes in Aß Cirach M, Sánchez-Benavides G, Oct;16(10):1358-1371. pathology are detected. EMBO Mol Falcon C, Arenaza-Urquijo EM, Med. 2020 Dec 7;12(12):e12921. Gotsens X, Fauria K, Sunyer J, Arenaza-Urquijo EM, Salvadó G, Nieuwenhuijsen MJ, Luis Molinuevo J; Operto G, Minguillón C, Skouras S, Torner J, Andersson P, ALFA Study. Impact of urban Sánchez-Benavides G, Crous-Bou M, Koush Y, Falcon C, Minguillon C, environmental exposures on Grau-Rivera O, Sala-Vila A, Falcón C, Fauria K, Alpiste F, Blenow K, Zetter- cognitive performance and brain Suárez-Calvet M, Zetterberg H, berg H, Gispert JD, Molinuevo JL; ALFA structure of healthy individuals at Blennow K, Gispert JD, Molinuevo JL; Study. Earliest amyloid and tau risk for Alzheimer’s dementia. ALFA Study. Association of years to deposition modulate the inﬂuence Environ Int. 2020 May;138:105546. parent’s sporadic onset and risk of limbic networks during factors with neural integrity and closed-loop hippocampal downre- Schindler SE, Jicha GA, Nelson PT, Alzheimer biomarkers. Neurology. gulation. Brain. 2020 Mar Keene CD, Blennow K, Molinuevo JL, 2020 Oct 13;95(15):e2065-e2074. 1;143(3):976-992. Masters CL, Hansson O, Teunissen CE, Galasko D, Shaw LM, Levey AI, Sánchez-Benavides G, Salvadó G, Silverberg N. Maximizing Safety in Arenaza-Urquijo EM, Grau-Rivera O, the Conduct of Alzheimer’s Disease Suárez-Calvet M, Milà-Alomà M, Fluid Biomarker Research in the González-de-Echávarri JM, Minguillon Era of COVID-19. J Alzheimers Dis. C, Crous-Bou M, Niñerola-Baizán A, 2020;76(1):27-31. Perissinotti A, Gispert JD, Molinuevo Dissemination of results Annual report 2020 32

2.08

Dissemi- 1 2 nation of Relationship between Air pollution causes insomnia and changes damage to brain areas results in brain structure and linked to Alzheimer's cognition

In May 2020 we established, in In January 2020 we published the collaboration with the Barcelona results of a study that indicates that Institute for Global Health, that people people with insomnia have poorer most exposed to environmental cognitive performance and lower pollution have brain alterations in volume in brain regions aﬀected in regions aﬀected by Alzheimer's the early stages of Alzheimer's. disease.

The research, involving 1,683 On the other hand, we also detected cognitively healthy adults from that a greater exposure to green areas the Alpha Study, opens the door to comprehensively analyze the is beneﬁcial, since it helps to generate relationship between sleep quality more resilience to the disease. We and Alzheimer's risk. carried out the research with 958 participants from the Alfa Study. Changes in brain structure in people with insomnia. Annual report 2020 Dissemination of results 33

2.08

Main researchers of the study about the proximity to parental age at onset of Alzheimer's as a risk of developing the disease.

3 4

Proximity to parental New biomarkers to age at the onset of detect the preclinical Alzheimer's as a risk phase of Alzheimer's factor

In November 2020, we announced In August 2020 we detected that the the results of a new international proximity to the parental age of onset study led by the BBRC in which we of Alzheimer's symptoms is related, in revealed that a series of biomarkers, women, to a greater accumulation of both from cerebrospinal fluid and 290 beta-amyloid protein, responsible for blood, previously described to detect Participants the characteristic lesions of the the most advanced stage of Alzhei- disease. The research results also mer's, can also detect the stage pointed out that people who have preclinical disease. suffered episodes of anxiety or depression in the past have greater The results point to the potential role atrophy of the hippocampus, a brain of tau protein as a therapeutic target structure that is affected by Alzhei- for the prevention of dementia mer's in the early stages of the disease. associated with Alzheimer's, and will also allow to improve the selection The study, carried out on 290 of participants in clinical trials of the participants in the Alfa Study, will disease. The research was conducted improve the selection of participants on 381 participants in the Alfa+ in prevention clinical trials in the Study. future. Scholarships and competitive grants Annual report 2020 34

2.09

The BBRC obtained in 2020 a total Scholarships of 6 grants to carry out scientiﬁc projects. Obtaining these funds and guarantees the rigor, excellence, competitiveness and innovative competitive nature of the center's research, and allows us to advance in the preven- grants tion of Alzheimer's disease.

List of grants awarded:

1. ERC Starting Grant. European Research Council. Dr. Marc Suárez-Calvet. The European Research Council (ERC) awarded an ERC Starting Grant to Dr. Marc Suárez-Calvet, a neurolo- gist and researcher at the BBRC, to lead the HeBe project. The grant is endowed with 1,498,915 euros for the next ﬁve years.

The ERC Starting Grants are highly competitive and are aimed at researchers of excellence with postdoctoral experience of between 2 and 7 years, so that they can create their own research group and carry out cutting-edge research. Annual report 2020 Scholarships and competitive grants 35

2.09

2. Diagnostics Accelator - Digital Biomarkers. Alzheimer’s Drug Discovery Foundation. Dr. José Luis Molinuevo.

3. EIT Digital 2021. EIT Digital. Obtaining these Dr. Juan Domingo Gispert. funds guarantees the rigor, excellence, 4. competitiveness and R + D + I Projects 2019 - Modalities innovative nature "Research Challenges". Ministry of of the center's Science and Innovation, Govern- ment of Spain research. Dra. Eider M. Arenaza-Urquijo.

5. Covid-19 Cohort in Spain: Social dynamics, mental health and inequalities. Fundación ”la Caixa”. Dra. Eider M. Arenaza-Urquijo.

6 6. Grants Call for health promotion and support for patients and families: Beta-AARC project. Department of Health of the Generalitat de Catalunya. Conferences Annual report 2020 36

2.10

The COVID-19 pandemic also hit hard February 12 Congress of the Alzheimer’s October 22 - 30 Conferences at the Alzheimer's disease scientific Madrid (Spain) Association On line conferences, which each year bring Participation of Dr. José Luis Molinue- The BBRC team of researchers Participation of Dr. Juan Domingo together thousands of expert resear- vo in the conference "Biomarkers in presented more than twenty studies Gispert and Mahnaz Shekari at the chers in this field from around the neurodegenerative diseases: present at the Alzheimer's Association annual congress of the European world. and future" at the Quirónsalud Madrid International Conference 2020 Association of Nuclear Medicine University Hospital. between 2 outstanding research (EANM). Although several conferences were sessions, 4 oral presentations and canceled or postponed, many others April 2 - 5 16 scientific posters. The reference October 26 quickly adapted to the situation and On line congress for Alzheimer's research was On line were held online. Participación del Dr. Juan Domingo held for the first time virtually and Participation of Dr. Juan Domingo Gispert y el Dr. José Luis Molinuevo free of charge, from July 27 to 31, Gispert in the XXIV Annual Meeting en el Congreso Internacional en 2020. of the Catalan Neurology Society. Alzheimer y Parkinson (AD/PD). October 21 - 30 November 17 January 15 - 17 June 4 On line On line Miami (United States) On line Participation of Dr. Natàlia Vilor Participation of Dr. Juan Domingo Participation of Gemma Salvadó in the Participation of Dr. José Luis and Dr. Marta Crous in the annual Gispert in the XIV CIBER-BBN Annual congress Human Amyloid Imaging Molinuevo in the webinar “Alzheimer congress of the Spanish Epidemiology Conference. al día” of the Spanish Society of Society. January 30 Neurology. Valencia (Spain) Participation of Dr. José Luis From June 23 to July 3 Molinuevo in the ‘Neuroimaging On line Update Day’ of the Valencian Participation of Dr. José Luis Molinue- Society of Neurology. vo in the conference “Brain Health Services” organized by the Hôpitaux Universitaires Genève and CHUV.

June 26 On line Participation of Dr. Juan Domingo Gispert in an update session of the Alfa Study in Prevent Dementia. Annual report 2020 Conferences 37

2.10

The COVID-19 pandemic also hit hard February 12 Congress of the Alzheimer’s October 22 - 30 at the Alzheimer's disease scientific Madrid (Spain) Association On line conferences, which each year bring Participation of Dr. José Luis Molinue- The BBRC team The BBRC team of researchers Participation of Dr. Juan Domingo together thousands of expert resear- vo in the conference "Biomarkers in presented more than twenty studies Gispert and Mahnaz Shekari at the of researchers presented chers in this field from around the neurodegenerative diseases: present at the Alzheimer's Association annual congress of the European world. and future" at the Quirónsalud Madrid more than twenty International Conference 2020 Association of Nuclear Medicine University Hospital. studies at the Alzheimer's between 2 outstanding research (EANM). Although several conferences were Association International sessions, 4 oral presentations and canceled or postponed, many others April 2 - 5 Conference 2020 . 16 scientific posters. The reference October 26 quickly adapted to the situation and On line congress for Alzheimer's research was On line were held online. Participación del Dr. Juan Domingo held for the first time virtually and Participation of Dr. Juan Domingo Gispert y el Dr. José Luis Molinuevo free of charge, from July 27 to 31, Gispert in the XXIV Annual Meeting en el Congreso Internacional en 2020. of the Catalan Neurology Society. Alzheimer y Parkinson (AD/PD). October 21 - 30 November 17 January 15 - 17 June 4 On line On line Miami (United States) On line Participation of Dr. Natàlia Vilor Participation of Dr. Juan Domingo Participation of Gemma Salvadó in the Participation of Dr. José Luis and Dr. Marta Crous in the annual Gispert in the XIV CIBER-BBN Annual congress Human Amyloid Imaging Molinuevo in the webinar “Alzheimer congress of the Spanish Epidemiology Conference. al día” of the Spanish Society of Society. January 30 Neurology. Valencia (Spain) Participation of Dr. José Luis From June 23 to July 3 Molinuevo in the ‘Neuroimaging On line Update Day’ of the Valencian Participation of Dr. José Luis Molinue- Society of Neurology. vo in the conference “Brain Health Services” organized by the Hôpitaux Universitaires Genève and CHUV.

June 26 On line Participation of Dr. Juan Domingo Gispert in an update session of the Alfa Study in Prevent Dementia. trans forma tion.

We seek solutions and explore new ways to create relevant results.

We work to support families living with Alzheimer's through the therapeutic group program for caregivers. In 2020, despite the pandemic situation, the project continued to be adapted to the online format, and we oﬀered caregivers an individual emotional support intervention service during the months of conﬁnement.

In our blog we publish numerous articles with advice to face conﬁnement and restric- tions derived from COVID-19 with people with Alzheimer's. Likewise, we continue with our objective of changing the social perception of Alzheimer's through dissemination and awareness and by organizing talks, trainings and awareness actions. 03. Annual report 2020 Therapeutic groups 39

3.01

In 2020, the therapeutic groups The program counted on the subsidy Therapeutic program launched 19 new groups granted by the Ministry of Health, with the participation of 158 caregi- Social Services and Equality, charged groups vers of people with Alzheimer's in to the income tax allocation, from the Barcelona, Girona, Lleida, Tenerife, support of the Department of Labor, Seville, Alcalá de Henares, Madrid, Social Affairs and Families of the Vigo and Valencia. Generalitat of Catalonia, charged to the allocation of 0,7% of personal As a result of the health situation income tax and financing from the caused by Covid-19, the therapeutic Barcelona City Council, the Girona groups were moved online in May. Provincial Council, “la Caixa” Founda- Likewise, during the period of home tion, Santalucía, the Adey Foundation Since the beginning confinement, between March and and the Agbar Foundation. June, 207 individual emotional of the program in 2013, support interventions were carried 1,051 caregivers have out to caregivers electronically participated in the 111 through phone calls, email and free therapeutic WhatsApp. groups that have been carried out in centers 19 throughout the Therapeutic Spanish geography. groups

158 Caregivers Therapeutic groups Annual report 2020 40

3.01

Concerned about the possible The objective of therapeutic groups is worsening of dementia symptoms in to offer caregivers a space in which those with Alzheimer's and about the to share experiences and acquire well-being of their caregivers during knowledge and tools to improve the The therapy sessions confinement, in July we conducted a quality of care and the general aim to improve the survey of caregivers in our therapy well-being of caregivers. quality of life of caregi- groups. vers, a fact that has a direct impact on the The results of the study indicate that quality of care they the caregivers dedicated 4 more hours a day to their relatives, with 18 provide and the well-be- hours a day being the average time of ing of the people with their work, and 67% perceived a Alzheimer's in their worsening of the general health of care. their relative with Alzheimer's during confinement.

With the support of: Annual report 2020 Awareness and outreach activities 41

3.02

1 This is the ﬁrst state representative Awareness survey that oﬀers a detailed view of the perceptions, knowledge and and Attitudes and attitudes of the Spanish population perceptions of the regarding Alzheimer's and its outreach Spanish population research. activities about Alzheimer's

2 In September, the data from the survey “Attitudes and perceptions September 21: of the Spanish population about a day to forget Alzheimer's disease”, carried out by the Pasqual Maragall Foundation, were published. The results reveal that 2 out of 3 Spaniards have or have had in their environment a person On September 21, 2020, the Pasqual with Alzheimer's, and that this is the Maragall Foundation issued a position health condition that, along with so that World Alzheimer's Day is cancer, worries the population the #undíaparaolvidar (a day to forget). most. Only thanks to scientiﬁc research, such as that carried out by the BBRC, will we be able to ﬁnd a cure for the disease. Awareness and outreach activities Annual report 2020 42

3.02

We urge the Govern- ment to prioritize the protection of people in situations of dependency or fragility

In July, the Pasqual Maragall Founda- 4 tion presented a proposal to the non-permanent Commission for We request that Social and Economic Reconstruction Alzheimer's and of the Congress of Deputies to put at dementias be included the center the protection and care of people in situations of fragility or in the new Euthanasia dependency, who suﬀered the impact Law of the Covid-19 in an accused way.

It demanded the development of a new model of long-term care, at the Together with entities such as the residential and home level, and the Barcelona Association of Relatives of provision of suﬃcient resources to People with Alzheimer's (AFAB) or research diseases such as Alzheimer's. the Spanish Alzheimer's Confedera- tion (CEAFA), the Pasqual Maragall Foundation presented in the Congress of Deputies the document “On Alzheimer's disease and other dementias and the new euthanasia law”.

Before the beginning of the processing of the Proposal of the Organic Law for the Regulation of Euthanasia, entities and professionals related to Alzheimer's and dementias asked that Alzheimer's and other neurodegenerative diseases be considered in the new law, in addition to proposing various proposals for improvement. Annual report 2020 Awareness and outreach activities 43

3.02

Blog “Let's talk about Alzheimer's”

The Pasqual Maragall Foundation With the emergence of Covid-19, wants to answer the questions about starting in March a series of 14 Alzheimer's that aﬀected people, their articles was launched with tips for caregivers, family members and the managing the health crisis situation general public may ask. For this with people with Alzheimer's. reason, in June 2017, he launched the blog “Let's talk about Alzheimer's”, Throughout the year there were with rigorous, accurate and updated nearly 1.4 million visits to the blog. information on Alzheimer's. The medical website certiﬁcation https://blog.fpmaragall.org/ granted by the Barcelona College of Physicians guarantees the quality of its contents. In 2020, 48 new articles were published, reaching a total of 201. 1.4 million visits

48 New articles Awareness and outreach activities Annual report 2020 44

3.02

Project “Life Soundtrack”

In 2020 the Pasqual Maragall Founda- Despite the pandemic situation, the tion promoted a new edition of the participants remained in contact “Life Sound-track” project. during the conﬁnement through an exchange of videos with messages of encouragement and video calls, and the project continued until October, when the young people delivered the playlists to each one of the older people.

The objective of the project is to value the beneficial effects of music for Fourth-year ESO students (end of emotional well-being, promote Secondary) participated who, after a knowledge and awareness of Alzhei- training period, made personalized mer's disease and work on intergene- playlists with older people affected rational relationships. with cognitive impairment.

Check the video about the project:

With the support of: Annual report 2020 Awareness and outreach activities 45

3.02

own channel, and four streaming sessions were broadcast. More than 250 short films from all over the world participated in the contest for the IX Solé Tura Prize, finally awarded to the film “The sense of cocoa”. About 1,000 people registered for the sessions, which consisted of 34 screenings, post-screenings with directors and creators –with the intervention of the actor Viggo Mortensen-, round tables, conferences, workshops and a parallel exhibition.

7 8

Third edition Cycle of talks of the Brain Film Fest “Remember”

In 2020, a new From October 1 to 3, the Center for On Thursday 5, 12 and 19 November, digital platform for the Contemporary Culture of Barcelona the cycle of online talks on Alzheimer's festival was launched, (CCCB) hosted the third edition of the “Remember” took place, dedicated with a selection of 10 Brain Film Fest, of which the to the latest scientific advances in the recommended films on Pasqual Maragall Foundation is field of prevention, as well as offering Filmin's own channel, the promoter and co-organizer. It advice and recommendations for is the only international film festival people living with it disease up close. and four streaming dedicated to showing and promoting sessions were broadcast. the creation and dissemination of The meetings, which had more than short films about any aspect of the 1,800 registered and more than brain, its incredible capacities or also 600 live interactions, had the its diseases. participation of experts from the Pasqual Maragall Foundation and the In 2020, a new digital platform for the BBRC, as well as voices from other festival was launched, with a selection organizations linked to the well-being of 10 recommended films on Filmin's of the elderly and Alzheimer's. Awareness and outreach activities Annual report 2020 46

3.02

Pact for Science and Innovation

In November 2020, the Pasqual Maragall Foundation joined the Pact for Science and Innovation promoted by the Government of Spain.

The document represents an agree- ment between civil society and the government to increase resources, strengthen the role of ﬁnancial agencies, and attract and retain talent.

The Foundation's director, Arcadi Navarro, with the Minister of Science and Innovation, Pedro Taking advantage of the occasion that Duque, at the official presentation of the Pact. 9 the pact offered, the Foundation urged the Ministry of Science and State Board for the Innovation to develop concrete actions and to effectively promote a Rights of the Elderly more efficient public-private collaboration.

In December 2020, the Pasqual Maragall Foundation joined the The Table was State Table for the Rights of Older created in 2013 to join Persons to defend the dignity and the movement in 57 rights of this group. The Table, made countries to demand up of the main third sector entities a United Nations related to older people, was created Convention for the in 2013 to join the movement in 57 Human Rights of countries to demand a United Nations Convention for the Human Rights of Older People. Older People. The incorporation involved holding about twenty meetings with entities in the ﬁeld of older people and with political representatives. Annual report 2020 Awareness and outreach activities 47

3.02

11 12

Signature campaign The Last Mission “Sign for a future of the Peseta without Alzheimer's”

It is estimated that in Spanish The Pasqual Maragall Foundation households there are still 1,600 continued to promote the campaign million euros in pesetas without “Sign for a future without Alzheimer's exchange. In 2020, the deadline to disease”, during 2020. The initiative, change them to euros was expected which has been in operation since to end and, for this reason, the 2017, aims to involve society in the Pasqual Maragall Foundation gave search for solutions to Alzheimer's the peseta a Last Mission: to contribu- disease and to raise awareness in the te to Alzheimer's research. competent institutions make disease investigation a priority. The campaign “The last mission of the peseta” was launched in July with the 54.000 Throughout the year about 100,000 aim of collecting these coins from conversations people joined the initiative, adding a Spanish households to use them for at street level total of more than 470,000 signatu- research projects against Alzheimer's res since the beginning of the at the BBRC. campaign.

Awareness at street level

In 2020, informants from the Pasqual Maragall Foundation held conversations with a total of 54,000 people on the streets of various cities in Spain about the Foundation's projects to promote research on the disease. Awareness and outreach activities Annual report 2020 48

3.02

14 July 8 October 14 November 19 Online talk “Alzheimer's in times of Training for high school students on Informative talk on neuroimaging at Talks, seminars pandemic: scientific news and social Alzheimer's by Dr. Nina Gramunt. the Virolai School by Dr. Carles Falcón action” by Dr. Nina Gramunt and Dr. within the framework of Science and conferences Gonzalo Sánchez-Benavides at the November 5, 12 and 19 Week. Catalan Neurology Society. The cycle of talks “Remember”: three meetings in which we talk about the December 4 September 16 latest scientific advances in the field Webinar “Towards new ways of aging Online talk “Legal tools in Alzheimer's of prevention, as well as advice and and taking care of ourselves” with the January 14 disease" co-organized with the College recommendations for people living participation of Dr. Nina Gramunt in Talk “Can Alzheimer's be prevented?” of Notaries of Catalonia by Dr. Sandra with Alzheimer's, with the collabora- the framework of the Santalucía by Dr. Nina Gramunt at the Sant Poudevida and the notary Albert tion of Dr. Sandra Poudevida, Albert Commitment Month. Climent de Llobregat Town Hall. Domingo. Quiles from Amics de la Gent Gran, Fuensanta Gil from AFAB, Dr. Marc December 10 February 12 September 21 Suárez-Calvet and Dr. Eider Arenaza Webinar “Human rights in the context Talk “When you take care of yourself, Online talk by Dr. Nina Gramunt Urquijo. of dementias” with the participation of Alzheimer's takes a step back” about Alzheimer's prevention at the Cristina Maragall and Dr. Nina by Dr. Nina Gramunt at La Mútua Work Café Santander in Bilbao, within November 5 and 11 Gramunt, organized by the Pasqual de Granollers. the framework of World Alzheimer's Training “Cognitive aging”, within the Maragall Foundation, HelpAge Day and within the Smart Talks in framework of the “Always Accompa- International Spain and the Pilares February 19 Open cycle of Banco Santander. nied” program of the “la Caixa” Foundation within the framework of Informative talk about Alzheimer's Foundation, and “Aging, what are they the International Human Rights Day. disease to high school students at the October 2 and how to act in the face of cognitive Biomedical Research Park (BBRC). Conversations ”Alzheimer's and difficulties?” by Dr. Nina Gramunt for caregivers: challenges and percep- a course for CaixaBank delegates. April 30 tions” and “The strength of optimism”, Online talk about Alzheimer's and its with the participation of Dr. Nina prevention by Dr. Nina Gramunt in Gramunt, and round table “The value the framework of “The Safety and of caring”, by Dr. Sandra Poudevida, Health Week” of Cementos Molins. in the context of the Brain Film Fest.

June 15 “Online meeting for caregivers of relatives with Alzheimer's” by Dr. Sandra Poudevida and Glòria Mas. Annual report 2020 Awareness and outreach activities 49

3.02

June 15 “Online meeting for caregivers of relatives with Alzheimer's” by Dr. Sandra Poudevida and Glòria Mas. Awareness and outreach activities Annual report 2020 50

3.02

Social media in 2020 73 Thousand followers in networks

Facebook Twitter Linkedin Youtube

56,077 10,190 4,522 2,214 Followers Followers Followers Subscribers 26,604 4,036 2,330 527,720 Reactions Retweets Recommendations Views 2,424 8,760 964 Comments Likes Shares 8,275 7,565 Shares Mentions Annual report 2020 Awareness and outreach activities 51

3.02

Awards and distinctions

HR Excellence in Research’ Award

The European Commission honored the BBRC with the HR Excellence in Research Award - HRS4R.

With this recognition, the center can use the HR Excellence in Research seal as a center that oﬀers a stimula- ting and favorable work environment in accordance with the European Charter for Researchers and the Code of Conduct for the Recruitment of research personnel. con nec tion.

We work in a network and with a global vision; cooperating will make us go further.

Solidarity in 2020 did not stop. More than 7,000 people joined our project, propelling us with their commitment to a future without Alzheimer's. With them, there are already 45,000 partners, donors, patrons, initiatives and solidarity legacies willing to make it happen. Originality and reinvention prevailed in this unusual year as well, and individuals and organizations across the country came forward with unforgettable new fundraising ideas to beat Alzheimer's. 04. Annual report 2020 Partner and donor team 53

4.01

Partner and donor team In 2020, we welcomed 7,633 new partners and associates, who with their regular contributions help ﬁnance research and social projects, giving them stability and path.

Donations were also increased by injecting nearly 200,000 euros into the Pasqual Maragall Foundation 7,633 project. New partners

In short, in 2020, the Foundation had the support of a social base of 45,000 partners, partners, donors, patrons, initiatives and solidarity legacies willing to change the history of this disease. 41,290

33,657

24,508 Evolution of the number of partners 16,863

8,947 4,863 2,058

2014 2015 2016 2017 2018 2019 2020 Partner and donor team Annual report 2020 54

4.01

Thanks for keep looking.

Every 3 seconds a new case of Salvador dementia is diagnosed in the world. Partner and participant of the Alfa Study But more and more people like “Alzheimer's took my mother away little by little, almost without Salvador, Jordi, Meritxell and realizing it, one day she was gone and we couldn't say goodbye. Mercè do not look away. That is why I am a member and participant of the Alfa Study, because I want to help end this disease ”. Their conviction gives us strength to continue moving forward. With Jordi your help, one day we will be able Partner and collaborating entrepreneur to explain how we all beat this disease together. “Alzheimer's ran in our family through my sister, when she was only 58 years old. The impotence in the face of this disease gave me strength to collaborate with the Foundation ”.

Meritxell At the Pasqual Partner Maragall Foundation “I have lived this disease very closely and I do not want that and the Barcelonaβeta neither I nor my people have to go through the same thing again”. Brain Research Center we want to thank all the partners, donors, patrons, Mercè initiatives and solidarity Partner and participant of the Alfa Study legacies for their support “I will continue to contribute, I want to help break this stigma that during 2020. surrounds the disease, speak more and together to ﬁnd a solution” .

Listen to their testimony in this video: Annual report 2020 Unforgettable actions and entities 55

4.02

Unforgetta- 1 ble actions Empresas and entities solidarias

• Santalucía with Therapeutic Groups.

The pandemic forced the Santalucía supported in 2020 the “We are highly committed to the elderly cancellation in 2020 of organization and development of and their needs, and we believe that it is many of the charity events therapeutic groups for caregivers essential to also attend to the family that the Foundation organizes in the members who care for them. That is and solidarity initiatives Community of Madrid. why we want to take care of those who that are organized to collect care through this type of program, funds against Alzheimer's. A group therapy that quickly adapted which we are convinced will help them to the digital environment in times of in their day-to-day life”. However, thanks to 82 pandemic. In the words of Emma unforgettable ideas, we Marín, Corporate Director of Commu- nication and CSR of Santalucía: managed to raise 64,392 euros for research.

These are some of the unforgettable stories made in 2020.

82 Unforgettable ideas Unforgettable actions and entities Annual report 2020 56

4.02

• Tablets to contact family members.

The Ricoh company delivered 10 tablets and 5 routers to the Sophos residence, a participant in the “Life • The Solidarity Calendar Soundtrack” project of the Pasqual Maragall Foundation, so that residents of the MGS Foundation. with Alzheimer's could contact their families during conﬁnement. The Mutua General de Seguros Foundation managed, with the participation of its employees and mediators, to raise 10,000 euros within the framework of the “Solidari- ty Calendar” initiative for Alzheimer's research.

• Payroll against Alzheimer's

For the second consecutive year, more than 1,000 Óptica & Audiolo- gía Universitaria workers donated a small part of their payroll, managing to allocate 3,800 euros to the Pasqual Maragall Foundation.

• End of the “Smiles that heal” campaign

Mútua Granollers managed to raise 12,135 euros for Alzheimer's research with its annual “Smiles that cure” campaign, through various initiatives such as lottery sales or solidarity sports days. Annual report 2020 Unforgettable actions and entities 57

4.02

2 • Solidarity pedaling

Solidarity A group of Cementos Molins workers who are fond of mountain biking celebrations decided to link their sporting challenge to the solidarity challenge of raising funds for Alzheimer's research, and managed to raise a total of 1,154 • 150 km non-stop for a future euros. without Alzheimer's.

On December 4, 2020, Jaume Rigo undertook the challenge of running 150 kms without stopping to raise awareness about Alzheimer's in his entire town, Son Servera (Mallorca). In addition, he proposed to join eﬀorts to defeat the disease and obtained more than 6,000 euros for his research.

Solidarity celebrations

2020 was also the year of cancella- tions. Weddings and celebrations were Discover his challenge here: “The entrance to the goal that I received postponed overnight. Even so, some from the townspeople, colleagues, people adapted their celebrations to volunteers and relatives, together with the situation and they managed to the great visibility that we managed raise 15,000 euros thanks to them to give to Alzheimer's disease and the for the investigation. 6,618 € raised, was the best award I could receive” Jaume Rigo. Unforgettable actions and entities Annual report 2020 58

4.02

“At the pharmacy we are very aware of the special needs of families who are closely aﬀected by Alzheimer's. For this reason, when we learned about the Foundation's caregiver programs, we did not hesitate to become partners. Helping these people is as important as investigating the disease. In addition, with the Foundation we also learn to be better prepared to care for family members and caregivers ”.

Carme Mestres Head of Pharmacy Mestres

Christmas 4 solidarity lottery Unforgettable Shops and Pharmacies

For the first time, we promoted the sale of numbers from the National Lottery Christmas Draw with a In 2020 we started a new project: donation to benefit research projects unforgettable shops and pharma- to defeat Alzheimer's. In this first year cies. The pandemic came to halt its we raised 5,649 euros. progress, but despite this, 93 solidarity establishments joined the project.

Thanks to the solidarity of these entrepreneurs and small freelancers, their businesses are unforgettable, and they wear a seal that identiﬁes them as such to their customers and users. Annual report 2020 Solidarity wills 59

4.03

In 2020, more than a hundred people How can you include Solidarity were interested in bequeathing to the Fundación Pasqual next generations a future where they wills can grow old with dignity, fully Maragall in the last enjoying this stage of life. A future will and testament? without Alzheimer's, where no family has to suﬀer the consequences of this disease.

At the Pasqual Maragall Foundation You can donate a part of your estate we have already entered more than to the Foundation through a legacy 260,000 euros thanks to the gift. It could be a speciﬁc amount of solidarity will. Solidarity wills are money, a percentage of the value of an increasingly popular way of your estate, property, jewellery, collaborating, in 2019 in Spain 205 work of art, stock, etc. million euros were collected in this way that were allocated to the projects of various solidarity organizations.

María José Cortina To do so, it is not necessary to have If you have no heirs, you can designate Legatee of the Pasqual Maragall a great fortune or numerous proper- Fundación Pasqual Maragall as Foundation ties. The contribution, whatever the universal heir, bequeathing all of amount, is decisive to continue your estate, rights and/or stock to “I decided to write a will before a notary investigating. the Foundation. in favor of the Pasqual Maragall Foundation. I did it for several reasons: the ﬁrst, because with my legacy I would help future generations not suﬀer from this terrible disease. The second, because I thought that my mother, who had had If you wish to donate to more than Alzheimer's, would be happy and proud one person and/or institution, you can of my decision. I thought it would be a designate Fundación Pasqual Maragall tribute, a posthumous gift ”. as coheir, indicating the percentage assigned to each party.

For more information on how to make bequests, donations, become a member or organize solidarity actions, call 900 545 545 Joint liability carries tax beneﬁts, since the part of the inheritance granted to or send your query or proposal to: Source: Notaries Association of Catalonia (2020). the Foundation is not taxed with the 60 million € in solidarity arrivals to Catalonia in 2019 [email protected] inheritance tax. trust.

We build long-term projects and relationships based on trust.

We work with a policy of transparency, good practices and accountability.

05. Annual report 2020 About us 61

5.01

About us 1 2 The Pasqual The Barcelonaβeta Maragall Foundation Brain Research Center

The Pasqual Maragall Foundation is The Barcelonaβeta Brain Research a private non-profit organization that Center is the research center of the was born in April 2008, as a response Pasqual Maragall Foundation. It was to the commitment made by Pasqual launched in 2012 linked to the Transparency Maragall (former mayor of Barcelona Pompeu Fabra University, and with and good practices: and former president of the Generali- the participation of the “la Caixa” tat of Catalonia) when he publicly Foundation, and today it is an At the Pasqual Maragall announced that he had been diagno- international center of reference Foundation and the sed with Alzheimer's. in the prevention of Alzheimer's. Barcelonaβeta Brain The purpose of the Foundation is to Its mission is to provide innovative Research Center we achieve a future without Alzheimer's solutions to decipher and prevent have a policy and a and, therefore, its mission is to face biological changes and cognitive code of good practices the challenges posed by this and other dysfunction associated with in transparency and neurodegenerative diseases through neurodegenerative diseases. His accountability, and we scientific solutions, promoting and research team develops projects on adhere to the code of structuring the support of society to neuroimaging and primary and good scientific practices achieve it. secondary prevention of Alzheimer's, and actively participates in studies and of the Biomedical Likewise, it has worked from the international work groups focused on Research Park of beginning to change the social the prevention of the disease. Barcelona (PRBB). consideration of the disease and raise awareness about its effects through In the last 5 years, its researchers have dissemination. published more than 200 articles in prestigious international journals. Origin and destination of resources Annual report 2020 62

5.02

Origin and destination of resources Pasqual Maragall Foundation € 7,241,947

BBRC Research Center € 4,323,361 At the Pasqual Maragall Foundation we work to achieve a future without Alzheimer's through biomedical research. 37 % To achieve this, we invest most of the resources obtained in research programs Budget and communication and outreach actions to increase € 11,565,308 social support for our cause.

We also allocate a portion 63 % of the resources to attracting new funds to ensure the long-term sustainability of ongoing scientiﬁc programs. Annual report 2020 Origin and destination of resources 63

5.02

Total revenues € 11,565,308 2 % 1 % Current income € 11,449,856 Patrons, partners and donors (60%) € 6,861,005 37 % Research project (37%) € 4,184,075 Clinical trials (2%) € 233,168 Current Social area, public outreach income and institutional relations (1%) € 171,608

Adjustments for capital subsidies* € 113,108 60 % Financial income* € 2,344 *Not included in the graphic

Total expenditures € 11,271,219 5 % 4 % Current expenses € 11,171,219 Research program (61%) € 6,868,291 Investment on the network 10 % of partners and donors (20%) € 2,207,093 Current Communication and sensitivity (10%) € 1,126,316 expenses Social area, public outreach 20 % and institutional relations (5%) € 502,541 61 % Administration (4%) € 466,978

Financial expenses* € 65,320

*Not included in the graphic

Added data of the Pasqual Maragall Foundation and its research center, the Barcelonaβeta Brain Research Center. Data submitted to an annual audit of accounts. Collaborators Annual report 2020 64

5.03

Collabo- Consejo de mecenazgo rators Strategic Partners

Special Partners

Our most sincere thanks to the network of partners Partners and donors, and to the entities, companies and professionals that have supported our research through their contribu- Associated companies tions and collaborations.

Our recognition also to all the volunteers who dedicate their time to Academic and scientiﬁc partners us and help us in the organization of actions and events.

See the full list of Collaborating entities collaborators here: http://fpmaragall.org/memoria2020 Fundación Adey Ricoh Santalucía Seguros Óptica Universitaria La Mutua Llúria Fundación MGS Caprabo Annual report 2020 Academic collaborators 65

5.04

Amsterdam University Medical Centers Instituto Hospital del Mar de Investigaciones Médicas Academic Barcelona Supercomputing Center ISGlobal collabo- Centro de Regulación Genómica Karolinska Institute Centro Nacional rators de Investigaciones Cardiovasculares Leiden University Medical Center CIBER-BBN Philips CIBERFES Roche Diagnostics Consorcio AMYPAD Universitat Autònoma de Barcelona Consorcio EPAD University of Edinburgh Consorcio EUFINGERS University of Gothenburg Erasmus MC University Medical Universidad de Lund Center Rotterdam University of Wisconsin-Madison F. Hoﬀmann-La Roche Ltd. Universitat Politècnica de Catalunya GE Healthcare Universitat Pompeu Fabra Hospital Clínic de Barcelona University College of London Hospital Universitario Vall d’Hebron Instituto de Investigaciones Biomédicas August Pi i Sunyer

Barcelona Supercomputing Center. Board Annual report 2020 66

5.05

Board Executive commission

Honorary President President Pasqual Maragall Mira Montserrat Vendrell Rius

President Board members Cristina Maragall Garrigosa Jordi Camí Morell Lifetime chairperson Joaquim Coello Brufau Marcel Prunera Colomer 1st Vice President Conﬁguration Arcadi Navarro Cuartiellas Santiago de Torres Sanahuja from February Lifetime chairperson Secretary and Deputy Secretary 20211 (not trustees) 2nd Vice President Ignasi Costas Ruiz del Portal Montserrat Vendrell Rius (DWF-RCD) 3rd Vice President Alberto Ouro Fuente (DWF-RCD) Jordi Camí Morell Lifetime chairperson

Other lifetime chairpersons Guillem Maragall Garrigosa Narcís Serra Serra Airy Maragall Garrigosa

Board members Nuria Basi Moré Joaquim Coello Brufau Joaquim Boixareu Antolí María Carmen Garmendia Lasa Marta Grabulosa Areny Arcadi Navarro Cuartiellas Bancària Caixa d'Estalvis i Pensions de Barcelona Foundation, ”la Caixa” (representing Antonio Vila Bertrán, substitute: Àngel Font Vidal) Jordi Mercader Miró Pura Muñoz-Cánoves Marcel Prunera Colomer David Vegara Figueras

On behalf of the Patronage Council Fundación ACS (representing Antonio García Ferrer) Fundación Privada Banco Sabadell (representing Miquel Molins Nubiola)

Secretary and Deputy Secretary (not trustees) Ignasi Costas Ruiz del Portal Alberto Ouro Fuente Annual report 2020 Board 67

5.05

Board Executive commission

President President Montserrat Vendrell Rius Montserrat Vendrell Rius

Director Members Arcadi Navarro Cuartiellas Jordi Camí Morell Joaquim Coello Brufau Members Arcadi Navarro Cuartiellas Arcadi Navarro Cuartiellas Conﬁguration Marcel Prunera i Colomer Jordi Camí Morell from February ”la Caixa” Foundation Joaquim Coello Brufau (Antonio Vila Bertrán / Àngel Font Vidal) 20211 Universitat Pompeu Fabra (José Garcia Montalbo) Josep Martorell Rodon Francesc Posas Garriga Marcel Prunera i Colomer ”la Caixa” Foundation (Antonio Vila Bertrán / Àngel Font Vidal)

Secretary and Deputy Secretary (not trustees) Ignasi Costas Ruiz del Portal (DWF-RCD) Alberto Ouro Fuente (DWF-RCD)

20 20A key year for science

20 20

Annual Annual 20 report Annual report 2020 20 report

"Nowhere is it written that Alzheimer's is invincible"

Pasqual Maragall October, 2007

Wellington, 30 08005 Barcelona 933 160 990 [email protected] [email protected] www.fpmaragall.org www.barcelonabeta.org